---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-153427"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2025-07-01T23:59:59+00:00"
generated_at: "2026-05-18T10:18:32.854852+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Jade Biosciences appoints Brad Dahms as CFO, enters manufacturing agreement with Patheon for JADE101

## Summary
- Brad Dahms appointed CFO effective July 14, 2025; base salary $500K, target bonus 40%, option for 526,000 shares vesting over 4 years.
- Patheon MSA covers cGMP manufacturing for JADE101 and future programs; initial 5-year term with auto-renewal; non-cancellable fees per project.
- Dahms previously CFO of IDRx (sold to GSK), Theseus (sold to Concentra), and Selecta; brings 15 years biotech and investment banking experience.
- Company advancing JADE101 into clinic this year for IgA nephropathy; recent Nasdaq listing and private financing provide momentum.

## SEC filing metadata
- accession: 0001193125-25-153427
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2025-07-01T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000119312525153427/0001193125-25-153427-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000119312525153427/d71010d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-153427
- JSON: https://secwatch.observer/filing/0001193125-25-153427.json
- Plain text: https://secwatch.observer/filing/0001193125-25-153427.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.